Alcoholic fatty liver disease (ALD) is one of the primary causes of chronic liver diseases in the United States. In particular, ALD is becoming a prevalent health issue among veterans due to an increase in obesity, diabetes, post-traumatic stress disorder (PTSD), and drug abuse in conjunction with alcohol consumption. Disturbance of circadian rhythmicity is a risk factor for the development of liver and metabolic diseases. However, the association between the liver circadian clock and ALD remains an intriguing but unexplored research area. In addition, the most advanced analytical tools, such as transcriptomics (RNA- seq) and metabolomics (GC/MS), have not been well utilized to study ALD. Nuclear receptors are key liaisons between the molecular clock machinery and metabolic diseases. My laboratory has pioneered major discoveries in the in vivo function of small heterodimer partner (SHP, Nrob2) in hepatic bile acid and lipid metabolism. The proposed study is based on our newly discovered role of SHP in integrating the circadian clock, metabolic network, and the ER stress signaling in the liver. The overall objective is to establish an integrated molecular circadian network in alcohol mediated ER stress response and steatosis. The central hypothesis is that ethanol-binge alters rhythmic SHP expression in the liver, which in turn modulates Npas2 and the downstream targets in the ER stress signaling and lipogenesis pathways. Specifically, we will elucidate how alcohol, SHP and Npas2 coordinately control CHOP and SREBP1c gene transcription, protein stability, and activity, and establish the modulation by alcohol of the entie liver transcriptome and metabolome.
Aim #1 : To elucidate a SHP and alcohol mediated molecular circadian pathway that controls ER stress signaling;
Aim #2 : To determine the effect of liver specific Npas2 knockdown on the ER stress response and steatosis mediated by SHP and ethanol-binge;
and Aim #3 : To establish hepatic circadian transcriptome and metabolome networks interlocked by SHP and ethanol-binge. In addition to our unique in vivo mouse (SHP-/-) and in vitro cell models, new liver Npas2 knockdown mice will be generated and employed for the study. Our approach makes full use of molecular biology, systems biology, and genome wide high throughput analysis (RNA-seq and GC/MS) to address an important scientific question that is directly relevant to the health of veterans. This study is innovative both conceptually and in the implementation of experimental approaches. The planned experimental strategies are comprehensive, yet feasible. This project will uncover for the first time a novel interplay between alcohol and the liver circadian clock to control the ER stress response and hepatic lipid metabolism. The discoveries made from this study are highly likely to enable substantial advances in ALD research, making this project of high clinical significance and translational value.

Public Health Relevance

Both non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (ALD) are major causes of chronic liver diseases in the United States. In particular, ALD is becoming a major health issue among veterans that is associated with the prevalence of obesity, diabetes and behavioral risk factors such as smoking and drug abuse. Growing evidence suggests that disturbance of circadian rhythmicity is a risk factor for the development of liver and metabolic diseases. This study will uncover for the first time the interplays among ethanol consumption, rhythmic expression of genes, oscillation of metabolites, and ER stress signaling mediated by nuclear receptor SHP.

Agency
National Institute of Health (NIH)
Institute
Veterans Affairs (VA)
Type
Non-HHS Research Projects (I01)
Project #
1I01BX002634-01
Application #
8735466
Study Section
Gastroenterology (GAST)
Project Start
2015-10-01
Project End
2019-09-30
Budget Start
2015-10-01
Budget End
2016-09-30
Support Year
1
Fiscal Year
2016
Total Cost
Indirect Cost
Name
VA Connecticut Healthcare System
Department
Type
DUNS #
039624291
City
West Haven
State
CT
Country
United States
Zip Code
Yu, Ai-Ming; Ingelman-Sundberg, Magnus; Cherrington, Nathan J et al. (2017) Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO). Acta Pharm Sin B 7:241-248
Zhang, Li; Yang, Zhihong; Trottier, Jocelyn et al. (2017) Long noncoding RNA MEG3 induces cholestatic liver injury by interaction with PTBP1 to facilitate shp mRNA decay. Hepatology 65:604-615
Zhao, Yulan; Yang, Zhihong; Wu, Jianguo et al. (2017) High-mobility-group protein 2 regulated by microRNA-127 and small heterodimer partner modulates pluripotency of mouse embryonic stem cells and liver tumor initiating cells. Hepatol Commun 1:816-830
Yang, Zhihong; Ross, Ruth A; Zhao, Shi et al. (2017) LncRNA AK054921 and AK128652 are potential serum biomarkers and predictors of patient survival with alcoholic cirrhosis. Hepatol Commun 1:513-523
Song, Yongfeng; Liu, Chune; Liu, Xia et al. (2017) H19 promotes cholestatic liver fibrosis by preventing ZEB1-mediated inhibition of epithelial cell adhesion molecule. Hepatology 66:1183-1196
Tran, Melanie; Lee, Sang-Min; Shin, Dong-Ju et al. (2017) Loss of miR-141/200c ameliorates hepatic steatosis and inflammation by reprogramming multiple signaling pathways in NASH. JCI Insight 2:
Tran, Melanie; Wang, Li (2017) Preserving LXR by inhibiting T39: A step closer to treating atherosclerosis and steatohepatitis? Hepatology 65:741-744
Liangpunsakul, Suthat; Toh, Evelyn; Ross, Ruth A et al. (2017) Quantity of alcohol drinking positively correlates with serum levels of endotoxin and markers of monocyte activation. Sci Rep 7:4462
Choiniere, Jonathan; Wu, Jianguo; Wang, Li (2017) Pyruvate Dehydrogenase Kinase 4 Deficiency Results in Expedited Cellular Proliferation through E2F1-Mediated Increase of Cyclins. Mol Pharmacol 91:189-196
Wang, Li; Liangpunsakul, Suthat (2016) Circadian clock control of hepatic lipid metabolism: role of small heterodimer partner (Shp). J Investig Med 64:1158-61

Showing the most recent 10 out of 20 publications